COMMUNIQUÉS West-GlobeNewswire

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
07/07/2026
In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI- [...]
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07/07/2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
07/07/2026
Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported [...]
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07/07/2026
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Endogenex Announces Full Enrollment of the ReCET Clinical Study
07/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
07/07/2026
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company [...]
HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open
07/07/2026
Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depression Results support further [...]
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
07/07/2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
07/07/2026
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and [...]
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
07/07/2026
Investigational n.c.a. 177 Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July 7, 2026 – ITM Isotope Technologies [...]
Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
07/07/2026
Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in patients with Duchenne muscular dystrophy 1 Updated open-label extension data contribute to the [...]
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
07/07/2026
GLASGOW, Scotland, July 07, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing orally delivered full-spectrum microbiome therapeutics for [...]
Levicept Appoints Darlene Deptula-Hicks as CFO
07/07/2026
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a [...]
Transactions in connection with share buy-back program
07/07/2026
Company announcement no. 24 - 26 7 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
07/07/2026
Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data I ntroduces a first-of-its-kind [...]
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
07/07/2026
Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle TM AD study and design of Phase III PrevenTRON study in preclinical [...]
Rapid Nutrition Showcases HealthTech Strategy on Bloomberg Television
07/07/2026
Interview showcases the Company's implementation of intelligent technologies across consumer wellness and investor engagement, reinforcing its evolution into a scalable HealthTech platform LONDON, July 06, 2026 (GLOBE [...]
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
06/07/2026
AMF Regulated Information Châtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a [...]
Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF
06/07/2026
Informations Réglementées Châtillon, France, le 6 juillet (22 h 30 CET) 2026 Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : [...]

Pages